Please Wait.....

Report

North America Obesity Treatment Market

Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research

North America obesity treatment market is expected to reach USD 68,985.14 thousand by 2032 from USD 22,757.18 thousand in 2024, growing at a CAGR of 14.9% in the forecast period of 2025 to 2032.
Market Segmentation:
North America Obesity Treatment Market, Treatment Type (Pharmacological Treatments (Anti-obesity Drugs), Bariatric Surgery, Behavioral & Lifestyle Therapy, Non-Invasive/ Endoscopic Procedures, and Medical Devices & Technologies), Age Group (Adult Obesity Treatment, Geriatric Obesity Treatment, and Pediatric Obesity Treatment), Distribution Channel (Online Pharmacies, Retail Pharmacies, Weight Management Clinics, Hospital Pharmacies, and Wellness & Fitness Centers), Patient Type (Class III, Class II, and Class I), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2032

Overview of North America Obesity Treatment market Dynamics:

Driver

- Integration of Digital Health Solutions in Obesity Treatment

Restraint

- Anti-Obesity Drugs and Surgical Interventions Carry Risks

Opportunity

- Increasing Prevalence of Lifestyle Related Diseases

Market Players:

The key market players operating in the North America obesity treatment market are listed below:

- Novo Nordisk A/S
- Eli Lilly and Company
- Medtronic Plc.
- Boston Scientific Corporation
- Johnson & Johnson Services, Inc.
- AstraZeneca
- Sanofi
- Allurion Technologies
- Reshape Lifesciences
- Currax Pharmaceuticals LLC
- Arena Pharmaceuticals Ltd
- VIVUS LLC.
- Noom, Inc.
- Omada Health Inc
- USGI Medical
- GSK plc
- Morphic Medical, Inc.
- Altimmune.

TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF THE NORTH AMERICA OBESITY TREATMENT MARKET 43
1.4 CURRENCY AND PRICING 44
1.5 LIMITATIONS 44
1.6 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 DBMR TRIPOD DATA VALIDATION MODEL 51
2.5 MULTIVARIATE MODELLING 54
2.6 TREATMENT TYPE LIFELINE CURVE 54
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.8 DBMR MARKET POSITION GRID 56
2.9 MARKET END USER COVERAGE GRID 57
2.10 VENDOR SHARE ANALYSIS 58
2.11 SECONDARY SOURCES 59
2.12 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 65
4.1 PORTER'S FIVE FORCES 66
4.2 PESTEL ANALYSIS 67
4.3 EPIDEMIOLOGY: NORTH AMERICA OBESITY TREATMENT MARKET 68
4.4 DRUG TREATMENT RATE BY MATURED MARKETS: NORTH AMERICA OBESITY TREATMENT MARKET 75
4.5 DRUG 82
4.6 WORD PIPELINE 85
5 REGULATORY FRAMEWORK FOR THE NORTH AMERICA OBESITY TREATMENT MARKET 117
5.1 REGULATORY APPROVAL PATHWAYS 119
5.2 LICENSING AND REGISTRATION 119
5.3 REGULATORY APPROVAL PATHWAYS 120
5.4 LICENSING AND REGISTRATION 120
5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 121
6 MARKET OVERVIEW 122
6.1 DRIVERS 124
6.1.1 INCREASING PREVALENCE OF OBESITY 124
6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS 126
6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES. 127
6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT 127
6.2 RESTRAINTS 129
6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS 129
6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY 129
6.3 OPPORTUNITIES 130
6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES 130
6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS 131
6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS 131
6.4 CHALLENGES 132
6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT 132
6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES 132
7 NORTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE 134
7.1 OVERVIEW 135
7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) 138
7.2.1 GLP-1 RECEPTOR AGONISTS 138
7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS 138
7.2.2.1 Phentermine 139
7.2.2.2 Phentermine-Topiramate 139
7.2.2.3 Naltrexone-Bupropion 139
7.2.3 LIPASE INHIBITORS 139
7.2.4 DEOXYCHOLIC ACID 139
7.2.5 OTHERS 139
7.3 BARIATRIC SURGERY 139
7.3.1 RESTRICTIVE SURGERIES 140
7.3.1.1 Sleeve gastrectomy 140
7.3.1.2 Adjustable gastric banding 140
7.3.2 COMBINATION SURGERIES 141
7.3.2.1 Roux-en-Y gastric bypass (RYGB) 141
7.3.2.2 Mini-gastric bypass (MGB) 141
7.3.3 MALABSORPTIVE SURGERIES 141
7.3.3.1 Laparoscopic Surgery 141
7.3.3.2 Robotic-Assisted Surgery 141
7.3.3.3 Open Surgery 141
7.4 BEHAVIORAL & LIFESTYLE THERAPY 142
7.4.1 DIETARY INTERVENTIONS 142
7.4.2 BEHAVIORAL MODIFICATION THERAPY 142
7.4.3 PHYSICAL ACTIVITY PROGRAMS 142
7.4.4 PSYCHOLOGICAL COUNSELING 142
7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES 143
7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG) 143
7.5.2 INTRAGASTRIC BALLOON (IGB) 144
7.5.2.1 Orbera intragastric balloon 144
7.5.2.2 Spatz adjustable balloon system 144
7.5.3 ASPIRATION THERAPY (ASPIREASSIST) 144
7.5.4 TRANSORAL GASTROPLASTY (TOGA) 144
7.6 MEDICAL DEVICES & TECHNOLOGIES 145
7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS 145
7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM) 145
8 NORTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP 146
8.1 OVERVIEW 147
8.2 ADULT OBESITY TREATMENT 150
8.3 GERIATRIC OBESITY TREATMENT 150
8.4 PEDIATRIC OBESITY TREATMENT 151
9 NORTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL 152
9.1 OVERVIEW 153
9.2 ONLINE PHARMACIES 156
9.3 RETAIL PHARMACIES 156
9.4 WEIGHT MANAGEMENT CLINICS 157
9.5 HOSPITAL PHARMACIES 157
9.6 WELLNESS & FITNESS CENTERS 158
10 NORTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE 159
10.1 OVERVIEW 160
10.2 CLASS III 163
10.3 CLASS II 163
10.4 CLASS I 164
11 NORTH AMERICA OBESITY TREATMENT MARKET, BY REGION 165
11.1 NORTH AMERICA 167
11.1.1 U.S. 172
11.1.2 MEXICO 177
11.1.3 CANADA 182
12 NORTH AMERICA OBESITY TREATMENT MARKET, COMPANY LANDSCAPE 187
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 187
13 SWOT ANALYSIS 188
14 COMPANY PROFILE 189
14.1 NOVO NORDISK A/S 189
14.1.1 COMPANY SNAPSHOT 189
14.1.2 REVENUE ANALYSIS 189
14.1.3 COMPANY SHARE ANALYSIS 190
14.1.4 PRODUCT PORTFOLIO 190
14.1.5 RECENT DEVELOPMENT 191
14.2 ELI LILLY AND COMPANY 192
14.2.1 COMPANY SNAPSHOT 192
14.2.2 REVENUE ANALYSIS 192
14.2.3 COMPANY SHARE ANALYSIS 193
14.2.4 PRODUCT PORTFOLIO 193
14.2.5 RECENT DEVELOPMENT/NEWS 194
14.3 MEDTRONIC 195
14.3.1 COMPANY SNAPSHOT 195
14.3.2 REVENUE ANALYSIS 195
14.3.3 COMPANY SHARE ANALYSIS 196
14.3.4 PRODUCT PORTFOLIO 196
14.3.5 RECENT DEVELOPMENT 197
14.4 BOSTON SCIENTIFIC CORPORATION 198
14.4.1 COMPANY SNAPSHOTS 198
14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 199
14.4.3 COMPANY SHARE ANALYSIS 199
14.4.4 PRODUCT PORTFOLIO 199
14.4.5 RECENT DEVELOPMENT 200
14.5 JOHNSON & JOHNSON SERVICES, INC. 201
14.5.1 COMPANY SNAPSHOT 201
14.5.2 REVENUE ANALYSIS 201
14.5.3 COMPANY SHARE ANALYSIS 202
14.5.4 PRODUCT PORTFOLIO 202
14.5.5 RECENT DEVELOPMENT/NEWS 203
14.6 ALTIMMUNE 204
14.6.1 COMPANY SNAPSHOT 204
14.6.2 PIPELINE PORTFOLIO 204
14.6.3 RECENT UPDATES 205
14.7 ASTRAZENECA 206
14.7.1 COMPANY SNAPSHOT 206
14.7.2 REVENUE ANALYSIS 206
14.7.3 PRODUCT PORTFOLIO 207
14.7.4 RECENT DEVELOPMENT/NEWS 207
14.8 ALLURION 209
14.8.1 COMPANY SNAPSHOT 209
14.8.2 REVENUE ANALYSIS 209
14.8.3 PRODUCT PORTFOLIO 210
1.1.5 RECENT DEVELOPMENT/NEWS 210
14.9 AMGEN 214
14.9.1 COMPANY SNAPSHOT 214
14.9.2 REVENUE ANALYSIS 214
14.9.3 PRODUCT PORTFOLIO 215
1.1.13 RECENT DEVELOPMENT/NEWS 215
14.10 ARENA PHARMACEUTICALS LTD 217
14.10.1 COMPANY SNAPSHOT 217
14.10.2 PRODUCT PORTFOLIO 217
14.10.3 RECENT DEVELOPMENT 217
14.11 CURRAX PHARMACEUTICALS LLC 218
14.11.1 COMPANY SNAPSHOT 218
14.11.2 PRODUCT PORTFOLIO 218
14.11.3 RECENT DEVELOPMENT 219
14.12 COUSIN SURGERY 220
14.12.1 COMPANY SNAPSHOT 220
14.12.2 PRODUCT PORTFOLIO 220
14.12.3 RECENT DEVELOPMENT 221
14.13 F. HOFFMANN-LA ROCHE LTD 222
14.13.1 COMPANY SNAPSHOT 222
14.13.2 REVENUE ANALYSIS 222
14.13.3 PRODUCT PORTFOLIO 223
14.13.4 RECENT DEVELOPMENT/NEWS 224
14.14 FITTERFLY HEALTHTECH PVT. LTD. 225
14.14.1 COMPANY SNAPSHOT 225
14.14.2 PRODUCT PORTFOLIO 225
14.14.3 RECENT DEVELOPMENT 226
14.15 MORPHIC MEDICAL, INC 227
14.15.1 COMPANY SNAPSHOT 227
14.15.2 PRODUCT PORTFOLIO 227
14.15.3 RECENT DEVELOPMENT 227
14.16 NOOM, INC. 228
14.16.1 COMPANY SNAPSHOT 228
14.16.2 PRODUCT PORTFOLIO 228
14.16.3 RECENT DEVELOPMENT 229
14.17 OMADA HEALTH INC 230
14.17.1 COMPANY SNAPSHOT 230
14.17.2 PRODUCT PORTFOLIO 230
14.17.3 RECENT DEVELOPMENT 230
14.18 RESHAPE LIFESCIENCES 231
14.18.1 COMPANY SNAPSHOT 231
14.18.2 REVENUE ANALYSIS 231
14.18.3 PRODUCT PORTFOLIO 232
1.1.7 RECENT DEVELOPMENT/NEWS 234
14.19 RAZIEL 237
14.19.1 COMPANY SNAPSHOT 237
14.19.2 PRODUCT PORTFOLIO 237
14.19.3 RECENT DEVELOPMENT 238
14.20 SPATZ FGIA INC. 239
14.20.1 COMPANY SNAPSHOT 239
14.20.2 PRODUCT PORTFOLIO 239
14.20.3 RECENT DEVELOPMENT 239
14.21 SANOFI 240
14.21.1 COMPANY SNAPSHOT 240
14.21.2 REVENUE ANALYSIS 240
14.21.3 PRODUCT PORTFOLIO 241
14.21.4 RECENT DEVELOPMENT 241
14.22 SANIONA 242
14.22.1 COMPANY SNAPSHOT 242
14.22.2 REVENUE ANALYSIS 242
14.22.3 PRODUCT PORTFOLIO 243
14.22.4 RECENT DEVELOPMENT 243
14.23 USGI MEDICAL 245
14.23.1 COMPANY SNAPSHOT 245
14.23.2 PRODUCT PORTFOLIO 245
14.23.3 RECENT DEVELOPMENT 245
14.24 VIVUS LLC. 246
14.24.1 COMPANY SNAPSHOT 246
14.24.2 PRODUCT PORTFOLIO 246
14.24.3 RECENT DEVELOPMENT/NEWS 247
14.25 VIKING THERAPEUTICS 249
14.25.1 COMPANY SNAPSHOTS 249
14.25.2 REVENUE ANALYSIS 249
14.25.3 PRODUCT PORTFOLIO 249
14.25.4 RECENT DEVELOPMENT 250
14.26 ZEALAND PHARMA 252
14.26.1 COMPANY SNAPSHOT 252
14.26.2 REVENUE ANALYSIS 252
14.26.3 PRODUCT PORTFOLIO 253
14.26.4 RECENT DEVELOPMENT/NEWS 254
15 QUESTIONNAIRE 255
16 RELATED REPORTS 258
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.